(Q51470666)

5 April 2018

title

Long-term efficacy and tolerability of acarbose treatment in patients with type 2 diabetes mellitus. (English)

1 reference

5 April 2018

1 reference

Pesach Segal

1

1 reference

5 April 2018

Haskel E Eliahou

2

1 reference

5 April 2018

Dieter Petzinna

3

1 reference

5 April 2018

Dieter Neuser

4

1 reference

5 April 2018

Andreas Brückner

5

1 reference

5 April 2018

Manfred Spengler

6

1 reference

5 April 2018

publication date

1 January 2005

1 reference

5 April 2018

Clinical Drug Investigation

published in

1 reference

5 April 2018

volume

25

1 reference

5 April 2018

issue

9

1 reference

5 April 2018

page(s)

589-595

1 reference

5 April 2018

Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study

cites work

1 reference

12 December 2020

Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs

1 reference

12 December 2020

Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas

1 reference

12 December 2020

What you always wanted to know about HbA1c

1 reference

12 December 2020

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

12 December 2020

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

1 reference

12 December 2020

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

1 reference

12 December 2020

Long-term improvement of metabolic control by acarbose in type 2 diabetes patients poorly controlled with maximum sulfonylurea therapy.

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the alpha-glucosidase inhibitor acarbose

1 reference

12 December 2020

A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.

1 reference

12 December 2020

A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1999

1 reference

12 December 2020

New Insights on Oxidative Stress and Diabetic Complications May Lead to a “Causal” Antioxidant Therapy

1 reference

12 December 2020

Effects of acarbose treatment in Type 2 diabetic patients under dietary training: a multicentre, double-blind, placebo-controlled, 2-year study

1 reference

12 December 2020

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

1 reference

12 December 2020

Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes

1 reference

12 December 2020

Combining sulfonylureas and other oral agents

1 reference

12 December 2020

Comparison of hemoglobin A1c and hemoglobin A1 in diabetic patients

1 reference

12 December 2020

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

12 December 2020

Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group.

1 reference

12 December 2020

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

1 reference

12 December 2020

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

12 December 2020

Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study

1 reference

12 December 2020

Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study

1 reference

12 December 2020

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies

1 reference

12 December 2020

10.2165/00044011-200525090-00004

Identifiers

DOI

1 reference

5 April 2018

PubMed ID

17532703

1 reference

5 April 2018